Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis

Category Primary study
JournalCLINICAL IMMUNOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 6959551161ab58d28e37f68acfb6eb570a8074d9
First added on: Nov 22, 2025